Furthermore, we found that in natalizumab untreated MS subjects, CD49d was up-regulated in both CD4+ and CD8+ T-lymphocytes naïve cells once a memory or effector phenotype was acquired. This evidence concerns the gene CD8A and myeloid sarcoma.